Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220)
Sponsor: Bristol-Myers Squibb
Summary
The purpose of this study is to assess the safety, tolerability, and surgical feasibility of preoperative Pumitamig-based therapy and other molecules in resectable, Early-Stage Non-Small Cell Lung Cancer
Official title: ROSETTA Lung-220: A Phase 2, Open-Label, Multicenter, Multi-Arm Platform Study Evaluating Pumitamig and Other Novel Neoadjuvant Regimens in Participants With Resectable, Early-Stage (IIA to IIIB) Non-Small Cell Lung Cancer
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
80
Start Date
2026-11-30
Completion Date
2028-03-15
Last Updated
2026-10-13
Healthy Volunteers
No
Conditions
Interventions
Pumitamig
Specified dose on specified days
Carboplatin
Specified dose on specified days
Cisplatin
Specified dose on specified days
Paclitaxel
Specified dose on specified days
Pemetrexed
Specified dose on specified days
Locations (50)
Local Institution - 0069
Long Beach, California, United States
Local Institution - 0127
Los Angeles, California, United States
Local Institution - 0136
Tampa, Florida, United States
Local Institution - 0155
Chicago, Illinois, United States
Local Institution - 0080
Chestnut Hill, Massachusetts, United States
Local Institution - 0163
Portland, Oregon, United States
Local Institution - 0132
Pittsburgh, Pennsylvania, United States
Local Institution - 0185
Nashville, Tennessee, United States
Local Institution - 0112
Houston, Texas, United States
Local Institution - 0023
Woolloongabba, Queensland, Australia
Local Institution - 0211
Fitzroy, Victoria, Australia
Local Institution - 0009
Murdoch, Western Australia, Australia
Local Institution - 0182
Calgary, Alberta, Canada
Local Institution - 0106
Oshawa, Ontario, Canada
Local Institution - 0061
Montreal, Quebec, Canada
Local Institution - 0022
Changsha Shi, Hunan, China
Local Institution - 0158
Shanghai, Shanghai Municipality, China
Local Institution - 0013
Chengdu, Sichuan, China
Local Institution - 0019
Beijing, China
Local Institution - 0212
Rennes, Brittany Region, France
Local Institution - 0015
Villejuif, Val-De-Marne, France
Local Institution - 0021
Toulouse, France
Local Institution - 0020
Paris, Île-de-France Region, France
Local Institution - 0205
Cologne, North Rhine-Westphalia, Germany
Local Institution - 0209
Moers, North Rhine-Westphalia, Germany
Local Institution - 0215
Hamburg, Germany
Local Institution - 0056
Aviano, Pordenone, Italy
Local Institution - 0044
Peschiera del Garda, Verona, Italy
Local Institution - 0203
Turin, Italy
Local Institution - 0005
Kitakyushu, Fukuoka, Japan
Local Institution - 0001
Yokohama, Kanagawa, Japan
Local Institution - 0004
Ōsaka-sayama, Osaka, Japan
Local Institution - 0153
Bydgoszcz, Kuyavian-Pomerania, Poland
Local Institution - 0087
Gdansk, Pomeranian Voivodeship, Poland
Local Institution - 0178
Bucharest, Bucharest, Romania
Local Institution - 0014
Cluj-Napoca, Cluj, Romania
Local Institution - 0024
Bucharest, Romania
Local Institution - 0200
Iași, Romania
Local Institution - 0006
Seoul, South Korea
Local Institution - 0007
Seoul, South Korea
Local Institution - 0038
Majadahonda, Madrid, Spain
Local Institution - 0052
Barcelona, Spain
Local Institution - 0055
Málaga, Spain
Local Institution - 0012
Taichung, Taiwan
Local Institution - 0017
Tainan, Taiwan
Local Institution - 0011
Taipei, Taiwan
Local Institution - 0216
Taipei, Taiwan
Local Institution - 0031
Leicester, East Midlands, United Kingdom
Local Institution - 0043
Metropolitan Borough of Wirral, North West, United Kingdom
Local Institution - 0049
London, United Kingdom